Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

22

Nov 2019

Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics

Onconova Therapeutics Inc a Phase stage biopharmaceutical company discovering and developing novel products to treat cancer with a focus on myelodysplastic syndromes MDS today announced they have entered into a Distribution License and Supply Agreement with Knight Therapeutics Inc Knight a Canadianb...

22

Nov 2019

Phenomics Health Inc. acquires patented drug metabolome technology

Phenomics Health Inc a precision medicine company based on the bioinformatics platform today announced that it has acquired Precera Bioscience based in Franklin Tennessee USA Patented drug metabolome technology portfolio

21

Nov 2019

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Dragonfly Therapeutics Dragonfly a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease and AbbVie NYSE ABBV a researchbased global biopharmaceutical company today announced a multitarget research collaboration designed to advance a number of...

21

Nov 2019

Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics

Astellas Pharma Inc and Welldoc Inc today announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions Under the agreement Astellas and Welldoc will jointly develop and commercialize BlueStar in...

20

Nov 2019

Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

Personalis Inc a leader in advanced genomics for cancer today announced a collaboration with Merck KGaA Darmstadt Germany a leading science and technology company to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies Merck KGaA Darmstadt Germany will utilize Pe...

20

Nov 2019

Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma Inctoday announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd Idorsia SIX IDIA to develop a novel drugdevice product combining selatogrel Idorsias potent fastacting and highly selective PY receptor antagonist under development with the Antares subcuta...

19

Nov 2019

Alkermes to Acquire Rodin Therapeutics

Alkermes plc and Rodin Therapeutics Inc Rodin today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin a privately held biopharmaceutical company focused on developing novel small molecule therapeutics for synaptopathies This transaction builds on Al...

19

Nov 2019

Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Dicerna Pharmaceuticals Inc and Novo Nordisk AS today announced an agreement to discover and develop novel therapies for the treatment of liverrelated cardiometabolic diseases using Dicernas proprietary GalXC RNAi platform technology The collaboration plans to explore more than liver cell targets a...

18

Nov 2019

WuXi AppTec's Lab Testing Division Expands Toxicology Facility in Suzhou, China

WuXi AppTec a leading global provider of RD and manufacturing services enabling companies in the pharmaceutical biotechnology and medical device industries today announced its Lab Testing Division LTD has expanded the Suzhou safety assessment facility by increasing toxicology capacity by to meet gl...

press releasesRead more...

22

Nov 2019

Glaukos Completes Acquisition of Avedro, Inc.

Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma corneal disorders and retinal diseases today announced that it has completed its previously announced acquisition of Avedro Inc

22

Nov 2019

ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

ProQR Therapeutics NV a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases today announced that it received Orphan Drug designation ODD from the Food and Drug Administration FDA for QR

21

Nov 2019

MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis

MC Therapeutics an emerging pharmaceutical company focused on novel PAD Technologybased topical therapies for chronic inflammatory conditions today announced that the US Food and Drug Administration FDA has accepted for review the New Drug Application NDA for Wynzora Cream

21

Nov 2019

Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

Kiniksa Pharmaceuticals Ltd a biopharmaceutical company focused on discovering acquiring developing and commercializing therapeutic medicines for patients with significant unmet medical need today announced that the US Food and Drug Administration FDA granted Breakthrough Therapy designation for ril...

21

Nov 2019

Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

Alnylam Pharmaceuticals Inc the leading RNAi therapeutics company announced today that the US Food and Drug Administration FDA approved GIVLAARI givosiran injection for subcutaneous use for the treatment of adults with acute hepatic porphyria AHP

20

Nov 2019

Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation

Sangamo Therapeutics Inc a genomic medicine company announced today that the United Kingdoms UK Medicines Healthcare Products Regulatory Agency MHRA has granted authorization of the firstinhuman clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell CARTreg therapy

20

Nov 2019

Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome

Newron Pharmaceuticals SpA a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system announced today that the US Food and Drug Administration FDA has granted the Rare Pediatric Disease designation for sarizotan t...

20

Nov 2019

The expanding and untouched South East Asia pharmaceutical market

The South East Asia region presents a diverse range of opportunities for multinational pharmaceutical firms During the emerging Asian region is experiencing key progress with respect to healthcare reforms shaping opportunities for local and foreign drugmakers A few trends are expected to persist in...

19

Nov 2019

FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions

Pfizer Inc today announced the United States US Food and Drug Administration FDA has approved ABRILADA adalimumabafzb as a biosimilar to Humira adalimumab for the treatment of certain patients with rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylosing spondylitis adult Cr...

EventsRead more...

26 - 27

Nov 2019

Dermatology & Cosmetology

Kiruthika
Holiday Inn Express Kuala Lumpur City Centre

26 - 28

Nov 2019

CPHI India 2019

India Epo Centre

27 - 28

Nov 2019

Frontiers in Organic and Analytical Chemistry

Larix International
Holiday Inn Express

28 - 29

Nov 2019

29 - 30

Nov 2019

Pharmaceutical R&D and Biopharmaceutics

Bioleagues world wide
Hong Kong

02 - 03

Dec 2019

Launch Readiness for Medical Affairs

Exl Events
Revere Hotel Boston Common

02 - 03

Dec 2019

Pediatrics and Neonatology

Rafael Hoteles Forum Alcala

02 - 03

Dec 2019

Dentistry and Oral Health

Scholars Conferences
Rafael Hoteles Forum Alcala

02 - 03

Dec 2019

Virtual Clinical Trials Conference

ExL Events
Philadelphia Rittenhouse Square

Advertisements

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    A Concise Treatise on Hard and Soft Nanomaterials for Drug Delivery

    Most of the conventional free drugs suffer from high side effects poor adsorption poor solubility high drug dosing minimum efficiency uncontrolled and nonspecific delivery with high cytotoxicity which limit their uses With respect to the chemotherapeutic drugs concern is more because most of the anticancer drugs are highly toxic for the healthy cells and damage the he...

EDITORIAL SECTION

  • STRATEGY

    REDUCTION OF HEALTH COSTS

    Since autumn the first package of costcutting measures in Switzerlands healthcare system is being reviewed One of the measures is the socalled refere...